NDATOPICALAEROSOL, FOAM
Approved
May 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
16
Data completeness
6/8 — Strong
FABIOR (tazarotene) by Design Pharmaceuticals is form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. First approved in 2012.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FABIOR (tazarotene) is a topical retinoid foam approved for acne vulgaris that works by binding to retinoic acid receptors (RARα, RARβ, RARγ) with selectivity for RARβ/γ. The drug exerts anti-hyperproliferative, normalizing-of-differentiation, and anti-inflammatory effects on skin. It is indicated for treatment of acne through modulation of gene expression and reduction of corneocyte accumulation.
$0.079BPart D
LOE Approaching3.7 years to LOEFABIOR is entering its final 3.7 years of patent protection with modest Part D penetration, indicating a mature specialty brand with constrained growth potential and likely smaller commercial team relative to peak-lifecycle products.
Mechanism of Action
form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical…
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Started Aug 2017
155 enrolled
Acne Vulgaris
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
Started Feb 2014
66 enrolled
Nail Psoriasis
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Started Jun 2010
59 enrolled
Acne Vulgaris
Worked on FABIOR at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.